Copyright © Queen's Printer,

Victoria, British Columbia, Canada

Licence

Disclaimer

Volume 54, No. 1

B.C. Reg. 2/2011

The British Columbia Gazette,

Part II

January 25, 2011

B.C. Reg. 2/2011 , deposited January 13, 2011, pursuant to the PHARMACY OPERATIONS AND DRUG SCHEDULING ACT [Section 22 (1)]. Regulation of the Board of the College of Pharmacists of British Columbia, dated September 24, 2010.

RESOLVED THAT, in accordance with the authority established in

section 22 (1) of the Pharmacy Operations and Drug Scheduling Act , and subject to filing with the Minister as required by

section 22 (2) of the Pharmacy Operations and Drug Scheduling Act , the board amend the Drug Schedules Regulation, B.C. Reg. 9/98, as set out in the

schedule attached to this resolution.

— M. MOLESCHI, Registrar .

Schedule

1 The Drug Schedules Regulation, B.C. Reg. 9/98, is amended in the Schedules

(

a) by striking out the following:

3 Diclofenac diethylamine (in preparations for topical use on the skin in concentrations of not more than 1% diclofenac)

3 Diphenhydramine and its salts and preparations (except for parenteral use or for topical use in concentrations of greater than 2%)

1 Fluconazole

1 Naltrexone and its salts , and

(

b) by adding the following:

3 Diclofenac diethylamine (in preparations for topical use on the skin in concentrations of not more than 1% diclofenac)

3 Diphenhydramine and its salts and preparations (except for parenteral use or for topical use in concentrations of greater than 2%)

1 Fluconazole

1 Naltrexone and its salts , and

(

b) by adding the following:

1 Ambrisentan

1 Dabigatran and its salts and derivatives

3 Diphenhydramine and its salts and preparations (except for parenteral use or for topical use in concentrations of 2% or less when sold in containers of 300 mg or less of diphenhydramine hydrochloride)

1 Etravirine and its salts

1 Fluconazole (except when sold in a concentration of 150 mg per oral dosage unit as a single dose treatment and indicated for the treatment of vaginal candidiasis)

3 Fluconazole (when sold in a concentration of 150 mg per oral dosage unit and indicated for the treatment of vaginal candidiasis, in package sizes containing no more than 150 mg of fluconazole)

1 Methoxy polyethylene glycol-epoetin beta

1 Naltrexone and its salts and derivatives

1 Nelarabine

1 Nepafenac

1 Nilotinib and its salts

1 Panitumumab

1 Retapamulin

1 Rivaroxaban

1 Sitagliptin and its salts

2 Sodium picosulphate for oral purgatives, 10 mg per pack (when found in preparations with magnesium oxide 3.5 g and citric acid 12

g) Copyright © 2011: Queen's Printer, Victoria, British Columbia, Canada